Boston Scientific (Natick, Massachusetts) and the Cordis unit (Miami Lakes, Florida) of Johnson & Johnson (J&J; New Brunswick, New Jersey) continued their marketing slugfest in the drug-eluting stent (DES) derby during the first quarter, with Boston Sci’s Taxus DES continuing to maintain its lion’s share of the sector.